INTRODUCTION
============

Compared with conventional endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) can achieve higher *en bloc* resection rates and lower recurrence rates \[[@b1-ce-2016-058]-[@b3-ce-2016-058]\]. ESD is considered the standard treatment of large, non-pedunculated, colorectal adenomas and early adenocarcinomas in Japan and some centers in Korea \[[@b4-ce-2016-058]-[@b6-ce-2016-058]\]. Given that the primary goal of endoscopic resection for colorectal neoplasia is to prevent colorectal cancer and reduce cancer-related mortality, *en bloc* resection is preferred, when feasible, to maximize the accuracy of the histologic assessment and to reduce the risk of local recurrence from incomplete excision, using piecemeal methods. Although ESD allows for *en bloc* resection of large colorectal lesions, it has several disadvantages compared to piecemeal EMR, including prolonged procedure time, technical difficulty, high risk of perforation, and the need for extended, in-hospital postoperative observation. In countries other than Japan, including the United States, colorectal ESD is rarely performed, and although it is becoming increasingly popular in Korea, it has not achieved universal acceptance.

Circumferential mucosal incision (CMI) followed by snare resection was first introduced by Japanese endoscopists to improve the *en bloc* resection rate of gastric epithelial neoplasms in 1988 \[[@b7-ce-2016-058]\]. This technique, often called endoscopic mucosal resection with circumferential mucosal incision (CMI-EMR, precut EMR), was designed to improve the *en bloc* resection rate of early neoplasms of the esophagus and stomach, where grasping flat lesions with a standard snare is often difficult. Its usefulness for early gastric cancers \<20 mm in size and small rectal carcinoid tumors is well established \[[@b8-ce-2016-058]-[@b11-ce-2016-058]\]. Recently, some Japanese and Korean studies reported that CMI-EMR could achieve a 65.2%--67% *en bloc* resection rate for large colorectal neoplasms with perforation rates of 0%--6.3% \[[@b12-ce-2016-058]-[@b14-ce-2016-058]\]. However, little is known about the efficacy and safety of CMI-EMR for large colorectal epithelial neoplasms, relative to ESD. Moreover, no data on CMI-EMR are available from Western centers with limited ESD experience.

We aimed to compare the efficacy of CMI-EMR and ESD as a treatment of large colorectal epithelial neoplasia by analyzing data from a Korean endoscopist with extensive experience in ESD \[[@b15-ce-2016-058]\] and a Western endoscopist with expertise in EMR and piecemeal resection, but with limited experience in ESD.

MATERIALS AND METHODS
=====================

General indications for CMI-EMR and ESD
---------------------------------------

Generally, lesions ≥20 mm in diameter, for which *en bloc* resection using the conventional EMR technique is considered difficult, were the main indications for colorectal ESD or CMI-EMR. In Korea, the procedures were performed by an endoscopist (DHY) at Asan Medical Center, Seoul. DHY received training in ESD by experts at Asan Medical Center \[[@b15-ce-2016-058]\] and performs 70--100 ESDs per year. In the United States, the procedures were performed by an endoscopist (SF) at Stanford University Hospital and VA Palo Alto, both in Palo Alto, California. SF had no clinical ESD experience at the start of the study period and received limited training through observation and performance of \<10 procedures in an animal lab.

Endoscopic submucosal dissection
--------------------------------

A high-definition endoscope (GIF-H260, GIF-Q260J, CFH260AI, CF-HQ290I, or PCF-Q260AL; Olympus Co., Tokyo, Japan) or a high-definition, magnifying colonoscope (CFFH260AZI; Olympus Co.) was used for the procedures performed in Korea. An electrosurgical unit (VIO300D; ERBE, Tubingen, Germany) was used during the procedure. The main device for mucosal incision and submucosal dissection consisted of a fixed flexible snare knife (Kachu Technology Co., Seoul, Korea), a dual knife (Olympus Co.), or a hybrid knife (ERBE, Tubingen, Germany). Sodium hyaluronate solution with a small amount of indigo carmine was used for the submucosal injection in all ESD procedures \[[@b5-ce-2016-058]\]. After careful inspection of the lesion, a submucosal cushion was created by injecting the solutions into the submucosal layer and the submucosal dissection was followed by a mucosal incision around the lesion. The details of the ESD technique have been previously described ([Fig. 1](#f1-ce-2016-058){ref-type="fig"}) \[[@b5-ce-2016-058],[@b15-ce-2016-058]\].

Endoscopic mucosal resection with circumferential mucosal incision
------------------------------------------------------------------

The endoscopes used for CMI-EMR were the same as those used for ESD. The procedures performed in the United States also involved high-definition colonoscopes (Pentax EC-3490L; Pentax, Montvale, NJ, or Olympus PCF-H180; Olympus Co., Center Valley, PA, USA). A fixed flexible snare knife, dual knife, or the tip of the snare (Captivator^TM^ II; Boston Scientific, Marlborough, MA, SD-230U-20; Olympus America, or Lariat^TM^; US Endoscopy, Mentor, OH, USA) was used for the CMI. An electrosurgical unit (VIO300D; ERBE) was used during the procedure (endocut Q with effect 2, cut duration 2 seconds and cut interval 6, or dry cut mode with effect 3 and 30 W for the mucosal incision). After meticulous endoscopic evaluation, saline mixed with methylene blue or indigo carmine was submucosally injected to lift the lesion. Epinephrine, sodium hyaluronate \[[@b5-ce-2016-058]\], methylcelluose \[[@b16-ce-2016-058],[@b17-ce-2016-058]\], hetastarch \[[@b18-ce-2016-058]\], and/or 10% glycerol \[[@b19-ce-2016-058]\] were occasionally incorporated into the injection fluid as needed, based on the characteristics of each lesion and the availability at each institution. A circumferential incision with a 2- to 5-mm lateral safety margin was made along the peripheral rim of the lesion. Unlike in ESD and its variant procedure, hybrid ESD \[[@b20-ce-2016-058]\], little or no submucosal dissection was performed after creating a groove around the mass by a circumferential incision. An opened snare was then fitted into the groove, and the lesion was grasped as a whole. Finally, the lesion was removed using electrical currents ([Fig. 2](#f2-ce-2016-058){ref-type="fig"}). Considering the loop diameter of each snare (SD-230U-20, Ø=20 mm; Lariat^TM^, Ø=30 mm; Captivator^TM^ II, Ø=33 mm), CMI-EMR was not attempted for lesions larger than 35 mm. In the case of eventual piecemeal resections, remnants were removed using additional hot snaring or hot biopsies.

Pre-medication and procedure-related patient care
-------------------------------------------------

All CMI-EMR procedures in the US were performed on outpatient basis, whereas most of the procedures in Korea, except for 2 CMI-EMR cases, were performed on inpatient basis. Prior to both procedures in Korea, 5 mg of cimetropium bromide was administered to reduce colonic peristaltic movements, whereas no antispasmodics were administered to the patients in the United States. Antiplatelet agents were discontinued for 7 days before the procedure if the patients had no or low cardiovascular risk. Aspirin was continued in the patients with high cardiovascular risk, regardless of the procedure type. Antiplatelet agents were resumed on the next day of the procedure in the patients with low or high cardiovascular risk, provided there was no hematochezia or melena. None of the patients in these cohorts was undergoing anticoagulation therapy.

Specimen histology
------------------

Specimens in the Korean center were spread and pinned onto Styrofoam boards immediately after endoscopic resection. They were fixed in 10% buffered formalin, paraffin-embedded, cut into 2-mm-thick slices, and evaluated. Specimens in the American centers were submitted for routine histopathology in accordance with standard hospital protocols, which include neither the spreading of the specimens nor the 2-mm-thick slicing for histologic evaluation; thus, the histologic complete resection rate based on the microscopic evaluation of the resection margin was not available in the American CMI-EMR cases. Submucosal invasion of the tumor to a depth of more than 1,000 µm from the muscularis mucosa was considered a deep submucosal invasive cancer.

Patient selection
-----------------

From July 2010 to July 2015, a total of 392 colorectal epithelial lesions ≥20 mm in size were treated by a Korean endoscopist (DHY) by using CMI-EMR (CMI-EMR group, *n*=34) or ESD (*n*=358) at the Asan Medical Center in Seoul, Korea. Because the size of the CMI-EMR cases ranged from 20--35 mm, 146 ESD cases that were larger than 35 mm were excluded. Then, size-matched (±3 mm) lesions were randomly recruited at a 1:3 ratio as comparative controls of the CMIEMR cases (size-matched ESD group) ([Fig. 3](#f3-ce-2016-058){ref-type="fig"}). From Sept 2012 to July 2015, 5 ESDs and 30 CMI-EMRs were performed by an American endoscopist (SF) for colorectal epithelial lesions ≥20 mm in size at Stanford Hospital or at the Veterans Administration Palo Alto Healthcare System in California. For comparison, the CMI-EMR cases performed by the Korean and American endoscopist were categorized as the Korean CMI-EMR group (*n*=34) and the US CMI-EMR group (*n*=30), respectively ([Fig. 3](#f3-ce-2016-058){ref-type="fig"}). Five ESD cases performed by the American endoscopist were not included in the analysis because of the small number of cases and different level of experience in ESD compared with that of the Korean endoscopist.

Data collection
---------------

All medical records were reviewed. Procedure-related outcomes including procedure time, *en bloc* resection rate, histologic complete resection rate, and adverse events were retrieved. The right colon was defined as the splenic flexure and the more proximal portions of the colon. The left colon was defined as the sigmoid colon and the descending colon up to but not including the splenic flexure. Local recurrence was evaluated when surveillance endoscopy was performed. All procedures were performed with informed consent. This retrospective case-control study was approved by the institutional review boards of the Asan Medical Center, the Stanford University School of Medicine, and the Veterans Administration Palo Alto Healthcare System.

Statistical analysis
--------------------

To assess the efficacy and safety of CMI-EMR relative to ESD, the procedure-related outcomes of the CMI-EMR and size-matched ESD groups were compared. Differences between CMI-EMRs performed by the Korean and the American endoscopist were also analyzed. Comparisons of continuous variables were performed using the Student's *t*-test. Dichotomous or categorical variables were compared using the chi-square test or Fisher's exact test. A *p*-value \<0.05 was considered statistically significant. Statistical analysis was performed with SPSS version 21.0 for Windows software (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Comparison between the CMI-EMR and ESD cases treated by a Korean endoscopist
----------------------------------------------------------------------------

Baseline characteristics and procedure-related outcomes of the CMI-EMR and size-matched ESD cases treated by a Korean endoscopist are provided in [Tables 1](#t1-ce-2016-058){ref-type="table"} and [2](#t2-ce-2016-058){ref-type="table"}. There were no significant differences in age or sex between the two groups. The lesion sizes were 22.3±3.9 mm (range, 20--35) and 22.9±2.4 mm (range, 20--35) in the CMI-EMR and size-matched ESD groups, respectively (*p*=0.268).

The resection time was significantly shorter in the CMI-EMR group than in the size-matched ESD group (12.7±7.0 min vs. 45.6±30.1 min, *p*\<0.001). The CMI-EMR group showed a tendency toward lower *en bloc* resection and histologic complete resection rates than the size-matched ESD group. All cases of piecemeal resection in the CMI-EMR group involved mucosal lesions, such as tubular adenoma (TA), tubulovillous adenoma (TVA), villous adenoma (VA), or sessile serrated adenoma/polyps (SSA/P). There were no differences in terms of postprocedural hemorrhage or perforation between the two groups. All perforations were successfully treated without surgery.

Surveillance endoscopy was performed in 21 (61.8%) of 34 patients in the Korean CMI-EMR group, with a median follow-up of 13.8 months (range, 2.5--39.1) and in 70 (68.6%) of 102 patients in the size-matched ESD group, with a median follow-up of 13.5 months (range, 0.9--50.6). There was no recurrence during surveillance in either group.

Comparison between the Korean CMI-EMR and US CMI-EMR groups
-----------------------------------------------------------

The mean age of the patients was older in the US CMI-EMR group than in the Korean CMI-EMR group. Continuation of the antiplatelet agents during the procedure was more common in the US CMI-EMR group than in the Korean CMI-EMR group. Variables related to lesion characteristics were not different between the two groups ([Table 3](#t3-ce-2016-058){ref-type="table"}). Resection time was significantly shorter in the Korean group than in the US group (12.7±7.0 min vs. 18.7±11.3 min, respectively, *p*=0.011). The *en bloc* resection rate was not statistically different between the groups (94.1% in the Korean CMI-EMR group and 80% in the US CMI-EMR group; *p*=0.133). One postprocedural hemorrhage and two perforations occurred in the Korean CMI-EMR group, while there were no procedure-related adverse events in the US CMI-EMR group; however, the difference in the frequency of procedure-related adverse events was not significant between the two groups. Procedure-related outcomes are presented in [Table 4](#t4-ce-2016-058){ref-type="table"}. Surveillance endoscopy was performed in 21 (61.8%) of 34 patients in the Korean CMI-EMR group, with a median follow-up of 13.8 months (range, 6.1--39.1), and in 9 (30%) of 30 patients in the US CMI-EMR group, with a median follow-up of 9.4 months (range, 2.5--21.2). There was no recurrence in either group.

DISCUSSION
==========

In our present study, we compared CMI-EMR and size-matched ESD for the resection of colorectal neoplasms with a diameter of 20--35 mm. The *en bloc* resection rate of the CMI-EMR group was comparable to that of the size-matched ESD group (94.1% vs. 100%). All of the piecemeal resection cases in the CMI-EMR groups were mucosal lesions, such as TA, TVA, VA, or SSA/P, for which piecemeal resection could be justified as a treatment option. Moreover, CMI-EMR required significantly less resection time than ESD (12.7±7.0 minutes vs. 45.6±30.1 minutes, respectively), and there was no difference in the rate of adverse events, such as postprocedural hemorrhage and perforation. Although no recurrences were found in either group, the follow-up duration was not sufficient to provide any conclusion about the difference in the recurrence rate between CMI-EMR and ESD. Nonetheless, considering the technical difficulty and longer procedure time for colorectal ESD, CMI-EMR may still be preferable, if the invasive cancers can be effectively excluded before endoscopic resection.

We consider that CMI-EMR is essentially a variation of the conventional EMR technique designed to achieve *en bloc* resection by making a circumferential groove that prevents the snare from slipping \[[@b7-ce-2016-058]\]. Because little or no submucosal dissection is required to make the circumferential groove \[[@b21-ce-2016-058]\], CMI-EMR is technically easier to perform than ESD and saves time by avoiding the trimming and submucosal dissection phases of ESD. Accordingly, CMI-EMR may provide acceptable procedure-related outcomes even if it is performed by an endoscopist with limited colorectal ESD experience. To explore this issue, we compared the outcomes of CMI-EMRs performed by an experienced Korean endoscopist (Korean CMI-EMR group) and those performed by an inexperienced American endoscopist (US CMI-EMR group). The procedure time in the US CMI-EMR group was significantly longer than that in the Korean CMI-EMR group. The gross *en bloc* resection rate and complication rate were not statistically different between these two groups, with a slight trend towards a lower *en bloc* rate and fewer complications in the US group. This suggests that extensive ESD experience is not necessary to achieve excellent results with CMI-EMR. The *en bloc* resection rates of CMI-EMR (80% in the US group and 94% in the Korean group) were favorable when compared with the reported *en bloc* resection rates of 53.5%--57.5% for 23--25 mm-colorectal polyps, using conventional EMR \[[@b22-ce-2016-058],[@b23-ce-2016-058]\].

Our study had several limitations. First, retrospective data from only two endoscopists with different experience levels were used in the analysis, and the number of cases was too small to discern subtle differences between the groups. Other potential biases, including the selection of cases for CMI-EMR, should also be considered when interpreting our results. Additional factors that can potentially affect *en bloc* resection and procedure times, such as submucosal fibrosis, redundancy of the colon, types of submucosal injection solutions, and bowel preparation quality, were not available or could not be investigated in sufficient detail in our analysis. Third, potential differences in the clinical situation at each center could not be analyzed. For example, all the procedures used in the Korean CMI-EMR ≥20 mm and ESD groups were performed in an inpatient setting, whereas all those of the US CMI-EMR group were performed in an outpatient setting. The endoscopist may be more cautious of adverse events in an outpatient setting, and thus may sometimes prefer piecemeal over *en bloc* resection to minimize the risk of perforation. In addition, the lack of rigorous histopathological specimen processing in American centers made it impossible to assess the histologic thoroughness of the resection as was done for the Korean data.

In conclusion, CMI-EMR for colorectal neoplasia 20--35 mm in size yields an excellent *en bloc* resection rate. Although CMI-EMR showed a trend toward lower *en bloc* resection rate than ESD, it has the advantage of shorter procedure time. Moreover, a Western endoscopist with limited experience in colorectal ESD performed CMI-EMR safely and achieved an *en bloc* resection rate comparable to that achieved by a Korean ESD expert, suggesting that expertise in ESD is not required for achieving appropriate clinical outcomes with CMI-EMR.
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![Representative example of an endoscopic submucosal dissection. (A) A laterally spreading tumor on the rectum. (B) The submucosal layer was exposed after precutting and trimming. (C) An additional submucosal dissection was performed. (D) After dissecting more than 75% of the lesion, a mucosal incision was made on the oral side. The scope was retroflexed in this image. (E) A clean-based artificial ulcer remained after complete excision of the lesion. (F) The lesion was removed *en bloc*.](ce-2016-058f1){#f1-ce-2016-058}

![Representative example of an endoscopic mucosal resection with circumferential mucosal incision. (A) A 20-mm-sized laterally spreading tumor was noted on the rectum. (B, C) After submucosal injection using sodium hyaluronate solution, a circumferential mucosal incision was performed using the tip of the snare. (D, E) The lesion was snared along with the circumferential groove and resected *en bloc*. (F) The lesion was identified as a villotubular adenoma with a high-grade dysplasia of 22×18 mm in size.](ce-2016-058f2){#f2-ce-2016-058}

![Selection of cases. (A) Case selection from among the ≥20-mm colorectal lesions that were removed using endoscopic mucosal resection with circumferential mucosal incision (CMI-EMR) or endoscopic submucosal dissection (ESD) at a Korean center. The size of the lesions removed using CMI-EMR ranged between 20 and 35 mm. After excluding lesions larger than 35 mm, size-matched ESD cases were randomly selected and matched with the CMI-EMR cases at a 1:3 ratio. (B) CMI-EMR cases performed by an experienced Korean endoscopist and an inexperienced American endoscopist were categorized as the Korean CMI-EMR group and the US CMI-EMR group, respectively.](ce-2016-058f3){#f3-ce-2016-058}

###### 

Baseline Characteristics of CMI-EMR and Size-Matched ESD Cases Treated by a Korean Endoscopist

  Variables                                                                    CMI-EMR group (34 lesions in 34 patients)   Size-matched ESD group (102 lesions in 100 patients^[a)](#tfn1-ce-2016-058){ref-type="table-fn"}^)   *p*-value
  ---------------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------------- -----------
  Age, yr, mean±SD                                                             61.6±8.0                                    62.2±10.1                                                                                            0.730
  Sex, male, *n* (%)                                                           18 (52.9)                                   61 (59.8)                                                                                            0.482
  Antiplatelet agents^[b)](#tfn2-ce-2016-058){ref-type="table-fn"}^, *n* (%)   1 (2.9)                                     1 (1.0)                                                                                              0.439
  Coagulopathy, *n* (%)                                                        0                                           0                                                                                                    NA
  Thrombocytopenia^[c)](#tfn3-ce-2016-058){ref-type="table-fn"}^, *n* (%)      1 (2.9)                                     0                                                                                                    0.250
  Size, mm, mean±SD                                                            22.3±3.9                                    22.9±2.4                                                                                             0.268
  Location^[d)](#tfn4-ce-2016-058){ref-type="table-fn"}^, *n* (%)                                                                                                                                                               0.289
   Right colon                                                                 19 (55.9)                                   45 (44.1)                                                                                            
   Left colon                                                                  8 (23.5)                                    21 (20.6)                                                                                            
   Rectum                                                                      7 (20.6)                                    36 (35.3)                                                                                            
  Morphology, *n* (%)                                                                                                                                                                                                           0.999
   Is                                                                          4 (11.8)                                    13 (12.7)                                                                                            
   II (IIa, IIb, or IIa + IIc)                                                 30 (88.2)                                   89 (87.3)                                                                                            
  Histology, *n* (%)                                                                                                                                                                                                            0.258
   TA, TVA, or VA                                                              28 (82.4)                                   81 (79.4)                                                                                            
   SSA/P                                                                       5 (14.7)                                    6 (5.9)                                                                                              
   Superficial submucosal cancer                                               1 (2.9)                                     8 (7.8)                                                                                              
   Deep submucosal cancer                                                      0                                           6 (5.9)                                                                                              
   Non-neoplastic lesions                                                      0                                           1 (1.0)                                                                                              

CMI-EMR, endoscopic mucosal resection with circumferential mucosal incision; ESD, endoscopic submucosal dissection; SD, standard deviation; NA, not applicable; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; SSA/P, sessile serrated adenoma/polyps.

Two patients had 2 synchronous lesions which were removed by using ESD technique.

Continued antiplatelet medication until the procedure date or \<7 days before the procedure.

Platelet count \<80×10^3^/mm^3^.

Right colon was defined as the splenic flexure and the more proximal portions of the colon. Left colon was defined as the sigmoid colon and descending colon.

###### 

Procedure-Related Variables of CMI-EMR and Size-Matched ESD Cases Treated by a Korean Endoscopist

  Variables                                CMI-EMR group (34 lesions)   Size-matched ESD group (102 lesions)   *p*-value
  ---------------------------------------- ---------------------------- -------------------------------------- -----------
  Device for mucosal incision                                                                                  \< 0.001
   Endoknife                               11 (32.4)                    102 (100)                              
   Tip of snare                            23 (67.6)                    0                                      
  Submucosal injection solution, *n* (%)                                                                       \< 0.001
   Saline-based solution only              12 (35.3)                    0                                      
   Sodium hyaluronate                      22 (64.7)                    102 (100)                              
  Resection time, minutes, mean±SD         12.7±7.0                     45.6±30.1                              \< 0.001
  Gross *en bloc* resection, *n* (%)       32 (94.1)                    102 (100)                              0.061
  Histologic complete resection, *n* (%)   26 (76.5)                    92 (90.2)                              0.075
  Complications                                                                                                
   Postprocedural hemorrhage, *n* (%)      1 (2.9)                      1 (1.0)                                0.439
   Perforation, *n* (%)                    2 (5.9)                      3 (2.9)                                0.599

CMI-EMR, endoscopic mucosal resection with circumferential mucosal incision; ESD, endoscopic submucosal dissection; SD, standard deviation.

###### 

Baseline Characteristics of CMI-EMR Cases That Were Performed by a Korean and an American Endoscopist

  Variables                                                                    Korean CMI-EMR group (*n*=34)   US CMI-EMR group (*n*=30)   *p*-value
  ---------------------------------------------------------------------------- ------------------------------- --------------------------- -----------
  Age, yr, mean±SD                                                             61.6±8.0                        67.6±7.9                    0.004
  Sex, male, *n* (%)                                                           18 (52.9)                       21 (70)                     0.163
  Antiplatelet agents^[a)](#tfn5-ce-2016-058){ref-type="table-fn"}^, *n* (%)   1 (2.9)                         7 (23.3)                    0.021
  Coagulopathy, *n* (%)                                                        0                               0                           NA
  Thrombocytopenia^[b)](#tfn6-ce-2016-058){ref-type="table-fn"}^, *n* (%)      1 (2.9)                         0                           0.999
  Size, mm, mean±SD                                                            22.3±3.4                        23.2±4.7                    0.405
  Location^[c)](#tfn7-ce-2016-058){ref-type="table-fn"}^, *n* (%)                                                                          0.331
   Right colon                                                                 19 (55.9)                       21 (70)                     
   Left colon                                                                  8 (23.5)                        3 (10)                      
   Rectum                                                                      7 (20.6)                        6 (20)                      
  Morphology, *n* (%)                                                                                                                      0.495
   Is                                                                          4 (11.8)                        6 (20)                      
   II (IIa, IIb, or IIa + IIc)                                                 30 (88.2)                       24 (80)                     
  Histology, *n* (%)                                                                                                                       0.604
   TA, TVA, or VA                                                              28 (82.4)                       21 (70)                     
   SSA/P                                                                       5 (14.7)                        8 (26.7)                    
   Superficial submucosal cancer                                               1 (2.9)                         1 (3.3)                     

CMI-EMR, endoscopic mucosal resection with circumferential mucosal incision; SD, standard deviation; NA, not applicable; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; SSA/P, sessile serrated adenoma/polyps.

Continued antiplatelet medication until the procedure date or \<7 days before the procedure.

Platelet count \<80×10^3^/mm^3^.

Right colon was defined as the splenic flexure and the more proximal portions of the colon. Left colon was defined as the sigmoid colon and descending colon.

###### 

Procedure-Related Variables of CMI-EMR Cases Performed by a Korean and an American Endoscopist

  Variables                                                          Korean CMI-EMR group (*n*=34)   US CMI-EMR group (*n*=30)                          *p*-value
  ------------------------------------------------------------------ ------------------------------- -------------------------------------------------- -----------
  Device for CMI-EMR or ESD, *n* (%)                                                                                                                    \< 0.001
   Endoknife                                                         11 (32.4)                       27 (90)                                            
   Tip of snare                                                      23 (67.6)                       3 (10)                                             
  Submucosal injection solution, *n* (%)                                                                                                                \< 0.001
   Saline-based solution only                                        12 (35.3)                       23 (76.7)                                          
   Adjuvant solution^[a)](#tfn8-ce-2016-058){ref-type="table-fn"}^   22 (64.7)                       7 (23.3)                                           
  Resection time, minutes, mean±SD                                   12.7±7.0                        18.7±11.3                                          0.011
  Gross *en bloc* resection, *n* (%)                                 32 (94.1)                       24 (80)                                            0.133
  Histologic complete resection, *n* (%)                             26 (76.5)                       NA^[b)](#tfn9-ce-2016-058){ref-type="table-fn"}^   NA
  Complications                                                                                                                                         
   Postprocedural hemorrhage, *n* (%)                                1 (2.9)                         0                                                  0.999
   Perforation, *n* (%)                                              2 (5.9)                         0                                                  0.494

CMI-EMR, endoscopic mucosal resection with circumferential mucosal incision; ESD, endoscopic submucosal dissection; SD, standard deviation; NA, not applicable.

Adjuvant solution indicates the use of sodium hyaluronate, methylcelluose, hetastarch, and/or 10% glycerol.

Specimens of American cases were submitted for routine histopathology in accordance with standard hospital protocols, which include neither spreading of the specimens nor 2 mm-thick slicing for histologic evaluation, and thus the histologic complete resection rate based on the microscopic evaluation of the resection margin was not available.
